down arrow

AIM ImmunoTech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00901B1052
USD
1.47
0.07 (5.0%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.411.51

52 Week

1.2836.00
Valuation
Technical
Day's Volume

CASH

45.98 k

Shareholding (Mar 2025)

FII

0.17%

Held by 7 FIIs

DII

95.39%

Held by 5 DIIs

Promoter

0.00%

How big is AIM ImmunoTech, Inc.?

22-Jun-2025

As of Jun 18, AIM ImmunoTech, Inc. has a market capitalization of 7.76 million, categorizing it as a Micro Cap company, with net sales of 0.15 million and a net profit of -15.22 million over the latest four quarters.

Market Cap: As of Jun 18, AIM ImmunoTech, Inc. has a market capitalization of 7.76 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, AIM ImmunoTech, Inc. reported net sales of 0.15 million and a net profit of -15.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -1.32 million and total assets of 51.49 million.

Read More

What does AIM ImmunoTech, Inc. do?

22-Jun-2025

AIM ImmunoTech, Inc. is a micro-cap specialty pharmaceutical company focused on developing immune-enhancing therapies for viral and immune-related disorders. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $7.76 million.

Overview:<BR>AIM ImmunoTech, Inc. is a specialty pharmaceutical company engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based chronic disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 7.76 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 1,694.08% <BR>Debt Equity: 0.02 <BR>Return on Equity: 373.68% <BR>Price to Book: -2.01 <BR><BR>Contact Details:<BR>Address: 2117 SW Highway 484, OCALA FL: 34473-7949 <BR>Tel: ['1 352 4487797', '1 888 5576480'] <BR>Fax: 1 352 4804620 <BR>Website: https://aimimmuno.com/

Read More

Who are in the management team of AIM ImmunoTech, Inc.?

22-Jun-2025

As of March 2022, the management team of AIM ImmunoTech, Inc. includes Dr. William Mitchell as Chairman of the Board, Mr. Thomas Equels as Executive Vice Chairman, CEO, President, Secretary, and General Counsel, and Mr. Stewart Appelrouth as a Director.

As of March 2022, the management team of AIM ImmunoTech, Inc. includes Dr. William Mitchell, who serves as the Chairman of the Board, and Mr. Thomas Equels, who holds multiple roles including Executive Vice Chairman, Chief Executive Officer, President, Secretary, and General Counsel. Additionally, Mr. Stewart Appelrouth is a Director on the board.

Read More

Is AIM ImmunoTech, Inc. technically bullish or bearish?

20-Sep-2025

As of July 17, 2025, AIM ImmunoTech's trend is mildly bullish with mixed signals from technical indicators, while it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -86.82% and -91.25%, respectively.

As of 17 July 2025, the technical trend for AIM ImmunoTech, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a monthly MACD that is mildly bullish and a monthly RSI that is bullish. However, the weekly MACD and KST are bearish, indicating some weakness in the shorter term. The daily moving averages are bearish, which adds to the mixed signals. The Bollinger Bands show a mildly bearish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, AIM ImmunoTech has significantly underperformed against the S&P 500 over the longer term, with a year-to-date return of -86.82% compared to the S&P 500's 12.22%, and a one-year return of -91.25% versus 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1,873.14%

stock-summary
Debt Equity

-0.26

stock-summary
Return on Equity

237.53%

stock-summary
Price to Book

-1.07

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-39.75%
0%
-39.75%
6 Months
-80.43%
0%
-80.43%
1 Year
-92.9%
0%
-92.9%
2 Years
-96.73%
0%
-96.73%
3 Years
267.32%
0%
267.32%
4 Years
11.36%
0%
11.36%
5 Years
-25.76%
0%
-25.76%

AIM ImmunoTech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is AIM ImmunoTech, Inc. technically bullish or bearish?

As of 17 July 2025, the technical trend for AIM ImmunoTech, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a monthly MACD that is mildly bullish and a monthly RSI that is bullish. However, the weekly MACD and KST are bearish, indicating some weakness in the shorter term. The daily moving averages are bearish, which adds to the mixed signals. The Bollinger Bands show a mildly bearish stance on both weekly and monthly time frames. In terms of performance, AIM ImmunoTech has significantly underperformed against the S&P 500 over the longer term, with a year-to-date return of -86.82% compared to the S&P 500's 12.22%, and a one-year return of -91.25% versus 17.14% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.65%
EBIT Growth (5y)
-5.31%
EBIT to Interest (avg)
-20.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.98%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.47
EV to EBIT
-0.32
EV to EBITDA
-0.33
EV to Capital Employed
-1.43
EV to Sales
5.60
PEG Ratio
NA
Dividend Yield
2320.50%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (4.44%)

Foreign Institutions

Held by 7 Foreign Institutions (0.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -55.56% vs 63.27% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-3.60",
          "chgp": "36.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "-0.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-1.80",
          "chgp": "-55.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-94,640.00%",
          "val2": "-73,880.00%",
          "chgp": "-2,076.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.34% vs -49.48% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.50",
          "val2": "-31.70",
          "chgp": "38.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.30",
          "val2": "-29.00",
          "chgp": "40.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-116,023.50%",
          "val2": "-157,930.70%",
          "chgp": "4,190.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-2.30
-3.60
36.11%
Interest
0.10
0.20
-50.00%
Exceptional Items
-0.30
-0.50
40.00%
Consolidate Net Profit
-2.80
-1.80
-55.56%
Operating Profit Margin (Excl OI)
-94,640.00%
-73,880.00%
-2,076.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -55.56% vs 63.27% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.20
Operating Profit (PBDIT) excl Other Income
-19.50
-31.70
38.49%
Interest
0.60
0.00
Exceptional Items
-0.50
-0.00
Consolidate Net Profit
-17.30
-29.00
40.34%
Operating Profit Margin (Excl OI)
-116,023.50%
-157,930.70%
4,190.72%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 40.34% vs -49.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AIM ImmunoTech, Inc. stock-summary
stock-summary
AIM ImmunoTech, Inc.
Pharmaceuticals & Biotechnology
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Company Coordinates stock-summary
Company Details
2117 SW Highway 484 , OCALA FL : 34473-7949
stock-summary
Tel: 1 352 44877971 888 5576480
stock-summary
https://aimimmuno.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."